

# Katsuhiko Naoki

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/7006831/katsuhiko-naoki-publications-by-year.pdf>

**Version:** 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

101  
papers

12,563  
citations

29  
h-index

112  
g-index

116  
ext. papers

13,799  
ext. citations

5  
avg, IF

5.03  
L-index

#	Paper	IF	Citations
101	Trends of concerns from diagnosis in patients with advanced lung cancer and their family caregivers: A 2-year longitudinal study. <i>Palliative Medicine</i> , <b>2021</b> , 35, 943-951	5.5	1
100	Prognostic significance of galectin-3 expression in patients with resected NSCLC treated with platinum-based adjuvant chemotherapy. <i>Thoracic Cancer</i> , <b>2021</b> , 12, 1570-1578	3.2	1
99	Upregulation of FGF9 in Lung Adenocarcinoma Transdifferentiation to Small Cell Lung Cancer. <i>Cancer Research</i> , <b>2021</b> , 81, 3916-3929	10.1	2
98	Implementation of clinical sequencing for molecular profiling in patients with advanced cancer. <i>Cancer Biomarkers</i> , <b>2021</b> , 31, 119-126	3.8	
97	Longitudinal Assessment of Prognostic Understanding in Patients with Advanced Lung Cancer and Its Association with Their Psychological Distress. <i>Oncologist</i> , <b>2021</b> , 26, e2265-e2273	5.7	1
96	Real-world assessment of afatinib for patients with EGFR-positive non-small cell lung cancer. <i>Investigational New Drugs</i> , <b>2020</b> , 38, 1906-1914	4.3	3
95	Survival and prognostic factors in elderly patients receiving second-line chemotherapy for relapsed small-cell lung cancer: Results from the Japanese Joint Committee of Lung Cancer Registry. <i>Lung Cancer</i> , <b>2020</b> , 146, 160-164	5.9	2
94	Impact of neutrophil-to-lymphocyte ratio in patients with EGFR-mutant NSCLC treated with tyrosine kinase inhibitors. <i>Investigational New Drugs</i> , <b>2020</b> , 38, 885-893	4.3	8
93	TRAP1 is a predictive biomarker of platinum-based adjuvant chemotherapy benefits in patients with resected lung adenocarcinoma. <i>Biomedical Research</i> , <b>2020</b> , 41, 53-65	1.5	4
92	The Clinical Impact of the Post-progression Survival on the Overall Survival in Elderly Patients or Those with a Poor Performance Status and Extensive-disease Small-cell Lung Cancer. <i>Japanese Journal of Lung Cancer</i> , <b>2020</b> , 60, 10-16	0.1	
91	Prognostic significance of NAP1L1 expression in patients with early lung adenocarcinoma. <i>Biomedical Research</i> , <b>2020</b> , 41, 149-159	1.5	5
90	Impact of Amrubicin Monotherapy as Second-Line Chemotherapy on Outcomes in Elderly Patients with Relapsed Extensive-Disease Small-Cell Lung Cancer. <i>Cancer Management and Research</i> , <b>2020</b> , 12, 4911-4921	3.6	2
89	Prognostic significance of IMMT expression in surgically-resected lung adenocarcinoma. <i>Thoracic Cancer</i> , <b>2019</b> , 10, 2142-2151	3.2	2
88	A phase II trial of induction of erlotinib followed by cytotoxic chemotherapy for EGFR mutation-positive non-squamous non-small cell lung cancer patients. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2019</b> , 84, 1065-1071	3.5	1
87	Impact of genotype on the efficacy of osimertinib in tyrosine kinase inhibitor-resistant patients with non-small cell lung cancer: a prospective observational study. <i>Cancer Management and Research</i> , <b>2019</b> , 11, 4883-4892	3.6	7
86	Molecular dynamics simulation-guided drug sensitivity prediction for lung cancer with rare mutations. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2019</b> , 116, 10025-10030	11.5	30
85	Evaluation of osimertinib efficacy according to body surface area and body mass index in patients with non-small cell lung cancer harboring an EGFR mutation: A prospective observational study. <i>Thoracic Cancer</i> , <b>2019</b> , 10, 880-889	3.2	8

84	Clinicopathological and prognostic significance of nuclear UGDH localization in lung adenocarcinoma. <i>Biomedical Research</i> , <b>2019</b> , 40, 17-27	1.5	6
83	Prognostic significance of G6PD expression and localization in lung adenocarcinoma. <i>Biochimica Et Biophysica Acta - Proteins and Proteomics</i> , <b>2019</b> , 1867, 38-46	4	19
82	Monomer Preference of EGFR Tyrosine Kinase Inhibitors Influences the Synergistic Efficacy of Combination Therapy with Cetuximab. <i>Molecular Cancer Therapeutics</i> , <b>2019</b> , 18, 1593-1601	6.1	2
81	Efficacy of afatinib or osimertinib plus cetuximab combination therapy for non-small-cell lung cancer with EGFR exon 20 insertion mutations. <i>Lung Cancer</i> , <b>2019</b> , 127, 146-152	5.9	29
80	Pharmacological and Structural Characterizations of Naquotinib, a Novel Third-Generation EGFR Tyrosine Kinase Inhibitor, in -Mutated Non-Small Cell Lung Cancer. <i>Molecular Cancer Therapeutics</i> , <b>2018</b> , 17, 740-750	6.1	18
79	Tumor associated macrophages support the growth of FGF9-induced lung adenocarcinoma by multiple mechanisms. <i>Lung Cancer</i> , <b>2018</b> , 119, 25-35	5.9	16
78	Efficacy of Platinum-Based Chemotherapy for Relapsed Small-Cell Lung Cancer after Amrubicin Monotherapy in Elderly Patients and Patients with Poor Performance Status. <i>Oncology</i> , <b>2018</b> , 94, 207-214	3.6	2
77	Real-world Efficacy and Safety of Nivolumab for Advanced Non-Small-cell Lung Cancer: A Retrospective Multicenter Analysis. <i>Clinical Lung Cancer</i> , <b>2018</b> , 19, e349-e358	4.9	36
76	Smoking History as a Predictor of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients with Non-Small Cell Lung Cancer Harboring EGFR Mutations. <i>Oncology</i> , <b>2018</b> , 95, 109-115	3.6	7
75	Comparison of detection methods of T790M mutations using plasma, serum, and tumor tissue in EGFR-TKI-resistant non-small cell lung cancer. <i>OncoTargets and Therapy</i> , <b>2018</b> , 11, 3335-3343	4.4	13
74	Amrubicin monotherapy for elderly patients with relapsed extensive-disease small-cell lung cancer: A retrospective study. <i>Thoracic Cancer</i> , <b>2018</b> , 9, 1279-1284	3.2	7
73	Comparison of carboplatin plus etoposide with amrubicin monotherapy for extensive-disease small cell lung cancer in the elderly and patients with poor performance status. <i>Thoracic Cancer</i> , <b>2018</b> , 9, 967-973	3.2	9
72	Secondary Brain Neoplasm after Stereotactic Radiosurgery in Patients with Metastatic Non-small Cell Lung Cancer. <i>Internal Medicine</i> , <b>2018</b> , 57, 2383-2387	1.1	2
71	Prognostic Understanding at Diagnosis and Associated Factors in Patients with Advanced Lung Cancer and Their Caregivers. <i>Oncologist</i> , <b>2018</b> , 23, 1218-1229	5.7	15
70	Targeted Therapy-induced Facial Skin Toxicities: Impact on Quality of Life in Cancer Patients. <i>Asia-Pacific Journal of Oncology Nursing</i> , <b>2018</b> , 5, 172-177	2.2	4
69	Prognostic significance of the 8th edition of the TNM classification for patients with extensive disease small cell lung cancer. <i>Cancer Management and Research</i> , <b>2018</b> , 10, 6039-6047	3.6	15
68	EGFR-mutant Non-small Cell Lung Cancer Accompanied by Transient Asymptomatic Pulmonary Opacities Successfully Treated with "Stop-And-Go" Osimertinib. <i>Internal Medicine</i> , <b>2018</b> , 57, 1007-1010	1.1	5
67	Development of Necrotizing Myopathy Following Interstitial Lung Disease with Anti-signal Recognition Particle Antibody. <i>Internal Medicine</i> , <b>2018</b> , 57, 2045-2049	1.1	10

66	Amplification of EGFR Wild-Type Alleles in Non-Small Cell Lung Cancer Cells Confers Acquired Resistance to Mutation-Selective EGFR Tyrosine Kinase Inhibitors. <i>Cancer Research</i> , <b>2017</b> , 77, 2078-2089	10.1	82
65	Clinical and pathological characteristics of EGFR mutation in operable early-stage lung adenocarcinoma. <i>Lung Cancer</i> , <b>2017</b> , 109, 45-51	5.9	26
64	A prospective cohort study of patients with non-squamous non-small cell lung cancer treated with bevacizumab. <i>Oncology Letters</i> , <b>2017</b> , 13, 3285-3290	2.6	2
63	Erlotinib as second- or third-line treatment in elderly patients with advanced non-small cell lung cancer: Keio Lung Oncology Group Study 001 (KLOG001). <i>Molecular and Clinical Oncology</i> , <b>2017</b> , 6, 409-414	1.6	8
62	Radiologic features of precancerous areas of the lungs in chronic obstructive pulmonary disease. <i>International Journal of COPD</i> , <b>2017</b> , 12, 1613-1624	3	12
61	Non-small cell lung cancer PC-9 cells exhibit increased sensitivity to gemcitabine and vinorelbine upon acquiring resistance to EGFR-tyrosine kinase inhibitors. <i>Oncology Letters</i> , <b>2017</b> , 14, 3559-3565	2.6	7
60	Phase I/II study of induction chemotherapy using carboplatin plus irinotecan and sequential thoracic radiotherapy (TRT) for elderly patients with limited-disease small-cell lung cancer (LD-SCLC): TORG 0604. <i>BMC Cancer</i> , <b>2017</b> , 17, 377	4.8	7
59	Overcoming EGFR Bypass Signal-Induced Acquired Resistance to ALK Tyrosine Kinase Inhibitors in ALK-Translocated Lung Cancer. <i>Molecular Cancer Research</i> , <b>2017</b> , 15, 106-114	6.6	36
58	Variant CD44 expression is enriching for a cell population with cancer stem cell-like characteristics in human lung adenocarcinoma. <i>Journal of Cancer</i> , <b>2017</b> , 8, 1774-1785	4.5	23
57	Characterization of the efficacies of osimertinib and nazartinib against cells expressing clinically relevant epidermal growth factor receptor mutations. <i>Oncotarget</i> , <b>2017</b> , 8, 105479-105491	3.3	27
56	The efficacy and safety of nivolumab in advanced non-small cell lung cancer in clinical practice in Japan: A multicenter analysis.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, e20577-e20577	2.2	
55	Activation of EGFR Bypass Signaling by TGF $\beta$ Overexpression Induces Acquired Resistance to Alectinib in ALK-Translocated Lung Cancer Cells. <i>Molecular Cancer Therapeutics</i> , <b>2016</b> , 15, 162-71	6.1	38
54	A Case of Non-Small Cell Lung Cancer with Possible "Disease Flare" on Nivolumab Treatment. <i>Case Reports in Oncological Medicine</i> , <b>2016</b> , 2016, 1075641	0.9	20
53	Successful treatment of non-small-cell lung cancer with afatinib and a glucocorticoid following gefitinib- and erlotinib-induced interstitial lung disease: A case report. <i>Molecular and Clinical Oncology</i> , <b>2016</b> , 5, 488-490	1.6	5
52	A phase II study of biweekly paclitaxel and carboplatin in elderly patients with advanced non-small cell lung cancer. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2015</b> , 75, 513-9	3.5	6
51	A Phase II study of S-1 and irinotecan combination therapy in previously treated patients with advanced non-small cell lung cancer. <i>Japanese Journal of Clinical Oncology</i> , <b>2015</b> , 45, 356-61	2.8	3
50	Mimicking the niche of lung epithelial stem cells and characterization of several effectors of their in vitro behavior. <i>Stem Cell Research</i> , <b>2015</b> , 15, 109-21	1.6	49
49	Characterization of the cell of origin and propagation potential of the fibroblast growth factor 9-induced mouse model of lung adenocarcinoma. <i>Journal of Pathology</i> , <b>2015</b> , 235, 593-605	9.4	20

48	Methylation-induced downregulation of TFPI-2 causes TMPRSS4 overexpression and contributes to oncogenesis in a subset of non-small-cell lung carcinoma. <i>Cancer Science</i> , <b>2015</b> , 106, 34-42	6.9	12
47	Long-term exposure to gefitinib induces acquired resistance through DNA methylation changes in the EGFR-mutant PC9 lung cancer cell line. <i>International Journal of Oncology</i> , <b>2015</b> , 46, 430-6	4.4	8
46	Multiple roles of extracellular fibroblast growth factors in lung cancer cells. <i>International Journal of Oncology</i> , <b>2015</b> , 46, 423-9	4.4	13
45	Prognostic implication of PTPRH hypomethylation in non-small cell lung cancer. <i>Oncology Reports</i> , <b>2015</b> , 34, 1137-45	3.5	18
44	Abstract 4: ABT-263 is effective in a subset of non-small cell lung cancer cell lines <b>2015</b> ,		2
43	Fatal Fulminant Pneumonia Caused by Methicillin-Sensitive Staphylococcus aureus Negative for Major High-Virulence Factors Following Influenza B Virus Infection. <i>American Journal of Case Reports</i> , <b>2015</b> , 16, 454-8	1.3	1
42	In vitro modeling to determine mutation specificity of EGFR tyrosine kinase inhibitors against clinically relevant EGFR mutants in non-small-cell lung cancer. <i>Oncotarget</i> , <b>2015</b> , 6, 38789-803	3.3	104
41	A phase II trial of induction Erlotinib followed by chemotherapy with Platinum + Pemetrexed +/- Bevacizumab for EGFR mutation-positive non-squamous non-small cell lung cancer patients.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, e19039-e19039	2.2	
40	FOXD1 expression is associated with poor prognosis in non-small cell lung cancer. <i>Anticancer Research</i> , <b>2015</b> , 35, 261-8	2.3	21
39	Claudin-1 is a novel target of miR-375 in non-small-cell lung cancer. <i>Lung Cancer</i> , <b>2014</b> , 85, 366-72	5.9	32
38	Expression of fibroblast growth factor 9 is associated with poor prognosis in patients with resected non-small cell lung cancer. <i>Lung Cancer</i> , <b>2014</b> , 83, 90-6	5.9	36
37	Clear cell sarcoma originating in the anterior mediastinum. <i>International Cancer Conference Journal</i> , <b>2013</b> , 2, 211-214	0.9	
36	Activation of the FGF2-FGFR1 autocrine pathway: a novel mechanism of acquired resistance to gefitinib in NSCLC. <i>Molecular Cancer Research</i> , <b>2013</b> , 11, 759-67	6.6	155
35	Identification of microRNAs differentially expressed between lung squamous cell carcinoma and lung adenocarcinoma. <i>Molecular Medicine Reports</i> , <b>2013</b> , 8, 456-62	2.9	51
34	Bacillus cereus necrotizing pneumonia in a patient with nephrotic syndrome. <i>Internal Medicine</i> , <b>2013</b> , 52, 101-4	1.1	12
33	Final result of phase II study of irinotecan (CPT-11) plus oral S-1 for previously treated advanced NSCLC patients.. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, e18058-e18058	2.2	
32	Bronchoscopic microsampling is a useful complementary diagnostic tool for detecting lung cancer. <i>Lung Cancer</i> , <b>2011</b> , 72, 32-8	5.9	17
31	The PCR-invader method (structure-specific 5Pnuclease-based method), a sensitive method for detecting EGFR gene mutations in lung cancer specimens; comparison with direct sequencing. <i>International Journal of Clinical Oncology</i> , <b>2011</b> , 16, 335-44	4.2	43

30	A phase I study of S-1 and irinotecan combination therapy in previously treated advanced non-small cell lung cancer patients. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2011</b> , 67, 717-22	3.5	2
29	The combination of multiple receptor tyrosine kinase inhibitor and mammalian target of rapamycin inhibitor overcomes erlotinib resistance in lung cancer cell lines through c-Met inhibition. <i>Molecular Cancer Research</i> , <b>2010</b> , 8, 1142-51	6.6	22
28	Prognostic and predictive gene signature for adjuvant chemotherapy in resected non-small-cell lung cancer. <i>Journal of Clinical Oncology</i> , <b>2010</b> , 28, 4417-24	2.2	350
27	Dose-escalating and pharmacokinetic study of a weekly combination of paclitaxel and carboplatin for inoperable non-small cell lung cancer: JCOG 9910-DI. <i>Japanese Journal of Clinical Oncology</i> , <b>2009</b> , 39, 569-75	2.8	4
26	Gene expression-based survival prediction in lung adenocarcinoma: a multi-site, blinded validation study. <i>Nature Medicine</i> , <b>2008</b> , 14, 822-7	50.5	835
25	An alternative method for screening EGFR mutation using RFLP in non-small cell lung cancer patients. <i>Journal of Thoracic Oncology</i> , <b>2008</b> , 3, 1096-103	8.9	38
24	Deregulation of histone lysine methyltransferases contributes to oncogenic transformation of human bronchoepithelial cells. <i>Cancer Cell International</i> , <b>2008</b> , 8, 15	6.4	120
23	Gene expression profiling reveals reproducible human lung adenocarcinoma subtypes in multiple independent patient cohorts. <i>Journal of Clinical Oncology</i> , <b>2006</b> , 24, 5079-90	2.2	207
22	A combination chemotherapy of carboplatin and irinotecan with granulocyte colony-stimulating factor (G-CSF) support in elderly patients with small cell lung cancer. <i>Lung Cancer</i> , <b>2006</b> , 53, 197-203	5.9	25
21	Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer. <i>Cancer Research</i> , <b>2005</b> , 65, 1479-88	10.1	470
20	Homozygous deletions and chromosome amplifications in human lung carcinomas revealed by single nucleotide polymorphism array analysis. <i>Cancer Research</i> , <b>2005</b> , 65, 5561-70	10.1	285
19	Interlaboratory comparability study of cancer gene expression analysis using oligonucleotide microarrays. <i>Clinical Cancer Research</i> , <b>2005</b> , 11, 565-72	12.9	116
18	Activating mutations of the noonan syndrome-associated SHP2/PTPN11 gene in human solid tumors and adult acute myelogenous leukemia. <i>Cancer Research</i> , <b>2004</b> , 64, 8816-20	10.1	404
17	PAF responsiveness in Japanese subjects with plasma PAF acetylhydrolase deficiency. <i>Biochemical and Biophysical Research Communications</i> , <b>2004</b> , 317, 205-10	3.4	14
16	EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. <i>Science</i> , <b>2004</b> , 304, 1497-500	33.3	7937
15	Hypercapnic acidosis attenuates endotoxin-induced nuclear factor- $\kappa$ B activation. <i>American Journal of Respiratory Cell and Molecular Biology</i> , <b>2003</b> , 29, 124-32	5.7	134
14	Missense mutations of the BRAF gene in human lung adenocarcinoma. <i>Cancer Research</i> , <b>2002</b> , 62, 7001-3	10.1	186
13	Effects of hypercapnia and hypocapnia on $[Ca^{2+}]_i$ mobilization in human pulmonary artery endothelial cells. <i>Journal of Applied Physiology</i> , <b>2001</b> , 90, 2094-100	3.7	19

12	Effect of steroid on hyperoxia-induced ICAM-1 expression in pulmonary endothelial cells. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , <b>2000</b> , 278, L245-52	5.8	29
11	Roles of ICAM-1 for abnormal leukocyte recruitment in the microcirculation of bleomycin-induced fibrotic lung injury. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2000</b> , 161, 1681-8	10.2	45
10	Nitric oxide differentially attenuates microvessel response to hypoxia and hypercapnia in injured lungs. <i>American Journal of Physiology - Regulatory Integrative and Comparative Physiology</i> , <b>1999</b> , 277, R181-9	3.2	5
9	Plasma platelet-activating factor acetylhydrolase deficiency in Japanese patients with asthma. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>1999</b> , 159, 974-9	10.2	34
8	Hyperoxia and hypercapnic acidosis differentially alter nuclear factor-kappa B activation in human pulmonary artery endothelial cells. <i>Advances in Experimental Medicine and Biology</i> , <b>1999</b> , 471, 265-70	3.6	4
7	Response of intra-acinar pulmonary microvessels to hypoxia, hypercapnic acidosis, and isocapnic acidosis. <i>Circulation Research</i> , <b>1998</b> , 82, 722-8	15.7	29
6	Impaired hypoxic vasoconstriction in intraacinar microvasculature in hyperoxia-exposed rat lungs. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>1998</b> , 158, 602-9	10.2	10
5	Differential contribution of various adhesion molecules to leukocyte kinetics in pulmonary microvessels of hyperoxia-exposed rat lungs. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>1998</b> , 157, 599-609	10.2	46
4	Modulation of Adhesion Molecule Expression in Pulmonary Vascular Endothelium by Oxygen <b>1998</b> , 479-483		
3	Sequential Multistep Mechanisms for Leukocyte Adhesion: Applicable to Lung Microcirculation? <b>1998</b> , 603-608		
2	Biological Impediment to Oxygen Sensing in Injured Pulmonary Microcirculation Exposed to a High-Oxygen Environment <b>1998</b> , 410-420		
1	Effects of active vasoconstriction and total flow on perfusion distribution in the rabbit lung. <i>American Journal of Physiology - Regulatory Integrative and Comparative Physiology</i> , <b>1997</b> , 273, R1465-73 <sup>3,2</sup>		4